Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 27:13:1099117.
doi: 10.3389/fonc.2023.1099117. eCollection 2023.

Clinical features and prognosis of pulmonary enteric adenocarcinoma: A retrospective study in China and the SEER database

Qike Wang  1 , Lu Zhang  1 , Huahua Li  1 , Linlin Liu  1 , Xu Sun  1 , Huaimin Liu  1
Affiliations

Clinical features and prognosis of pulmonary enteric adenocarcinoma: A retrospective study in China and the SEER database

Qike Wang et al. Front Oncol. .

Abstract

Objective: Pulmonary enteric adenocarcinoma (PEAC) is a rare subtype of pulmonary adenocarcinoma that lacks effective treatment. The purpose of this research was to investigate the clinical characteristics, treatment, and prognosis of PEAC, as well as the impact of relevant factors on survival, thus providing a reference for the clinical management of patients with this disease.

Methods: For this study, we gathered clinical data from 26 patients with PEAC in the Affiliated Cancer Hospital of Zhengzhou University from June 2014 to June 2021. We used SEER*Stat software V8.3.5 to download the PEAC patients from the Surveillance, Epidemiology, and End Results (SEER) database. In total, 20 patients were identified. Clinical data, including general information, imaging findings, and treatment protocols, were obtained, together with a follow-up of disease regression. The relevant clinical data were then analyzed.

Results: It included 12 males and 14 females out of 26 patients from China, whose mean age was (62.73 ± 11.89) years; 20 were in the lower lung, 11 were stage I-II, and 15 were stage III-IV. Five had EGFR mutations, and four had KRAS mutations. In terms of treatment, patients with stage I-II were primarily treated by surgery, and patients with stage III-IV were treated mostly by chemotherapy. We extended the follow-up date to January 2022. On completion of the follow-up visit, 11 patients died, and the remaining 15 patients survived. The overall survival (OS) of 26 patients was 2.0-76.0 months, while the mean was 53.1 months, and the median OS (mOS) was 38.0 months (95% CI:1.727-74.273). In the case of progression-free survival (PFS) times, it was 2.0-76.0 months, with a mean PFS of 31.0 months and a median PFS (mPFS) of 8.0 months (95% CI:4.333-11.667). The PFS of the 15 patients in stage III-IV was 2.0-17 months, while the mean PFS was 6.5 months and the mPFS was 6.0 months (95% CI:4.512-7.488). Out of the 20 patients identified in the SEER database, the average age was 69.9 years, with 14 males and 6 females. Of these patients, 8 were diagnosed with stage I-II, while the remaining 11 were diagnosed with stage III-IV. 10 underwent surgery, 4 received radiation therapy, and 9 received chemotherapy. The mean OS of the 20 patients was 67.5 months, mOS was 28.0 months (95% CI: 9.664- 46.336). For patients diagnosed with stage III-IV, the mean OS was 14.8 months and mOS was 20 months (95% CI: 4.713-35.287).

Conclusion: PEAC is rare, and the prognosis is determined mainly by the stage; patients who undergo surgery in stage I-II have a better prognosis.

Keywords: prognosis; pulmonary enteric adenocarcinoma; real word data; survival analysis; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Survival analysis of 26 patients from China. (A) Overall survival analysis of 26 patients. (B) Progression free survival analysis of 26 patients. (C) Overall survival analysis of stage III-IV. (D) Progression free survival analysis of stage III-IV.
Figure 2
Figure 2
Progression free survival analysis of patients with different chemotherapy modalities in stages III-IV from China.
Figure 3
Figure 3
Survival analysis of 20 patients from the SEER database. (A) Overall survival analysis of 20 patients. (B) Overall survival analysis of stage III-IV patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tsao MS, Fraser RS. PRIMARY PULMONARY ADENOCARCINOMA WITH ENTERIC DIFFERENTIATION. CANCER (1991) 68:1754–7. doi: 10.1002/1097-0142(19911015)68 - DOI - PubMed
    1. Truini A, Pereira PS, Cavazza A, Spagnolo P, Nosseir S, Longo L, et al. . Classification of different patterns of pulmonary adenocarcinomas. Expert Rev Respir Med (2015) 9:571–86. doi: 10.1586/17476348.2015.1083428 - DOI - PubMed
    1. Palmirotta R, Lovero D, D'Oronzo S, Todisco A, Interno V, Mele F, et al. . Pulmonary enteric adenocarcinoma: an overview. Expert Rev IN Mol Med (2020) 22:e1, 1–9. doi: 10.1017/erm.2020.2 - DOI - PubMed
    1. Li H, Cao W. Pulmonary enteric adenocarcinoma: a literature review. J Thorac Dis (2020) 12:3217–26. doi: 10.21037/jtd-19-4171 - DOI - PMC - PubMed
    1. Garajova I, Funel N, Fiorentino M, Agostini V, Ferracin M, Negrini M, et al. . MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. Clin Epigenet (2015) 7(1):1–7. doi: 10.1186/s13148-015-0162-5 - DOI - PMC - PubMed